globenewswire.com · 7 jul

Healthcare Realty Trust Announces Second Quarter Earnings Release Date and Conference Call

NASHVILLE, Tenn., July 07, 2026 (GLOBE NEWSWIRE) -- Healthcare Realty Trust Incorporated (NYSE:HR) today announced that on Thursday, July 30, 2026, after the market closes, it is scheduled to report results for the second quarter of 2026.

gurufocus.com · 15 jun

enGene Reports Second Quarter 2026 Financial Results and Provides Business Update

enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company today announced its financial

zacks.com · 8 jun

New Strong Buy Stocks for June 8th

EXPD, VNCE, UCTT, PRG and TNET have been added to the Zacks Rank #1 (Strong Buy) List on June 8, 2026.

gurufocus.com · 2 jun

Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6

Further positive results from the Phase III SERENA-6 trial showed AstraZeneca's camizestrant plus a cyclin-dependent kinase (CDK) 4/6 inhibitor – palbociclib

gurufocus.com · 31 may

Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMON

Summit Therapeutics Inc. (NASDAQ: SMMT) today announced positive overall survival (OS) results from the Phase III HARMONi-6 trial, conducted in China and spons

gurufocus.com · 30 may

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026

[url="]Exelixis, Inc.[/url] (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYXÂ

seekingalpha.com · 19 may

Healthcare Realty Trust: Betting On Outpatient Demand Growth, Lower Operator Risk (Upgrade)

Healthcare Realty Trust is well positioned in the outpatient medical REIT space, benefiting from macro trends like aging demographics and rising outpatient care demand. HR's growth is supported by a nationwide portfolio, strong tenant retention, and opportunities for property acquisitions and lease growth. Balance sheet risk is mitigated by competitive debt metrics and diversified asset exposure.

gurufocus.com · 15 may

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer

AstraZeneca and Daiichi Sankyo's ENHERTUÂ (fam-trastuzumab deruxtecan-nxki) has been approved by the US Food and Drug Administration (FDA) for both the neoadj